Alexandre Bazinet, M. D.
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2021 | McGill University, Montreal, CA, Experimental Medicine, Master of Science (MSc) |
| 2014 | McGill University, Montreal, QC, CA, Medicine, Medical Doctor and Master of Surgery (MDCM) |
Postgraduate Training
| 2021-2023 | Postgraduate Fellow, Leukemia Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2019-2021 | Residency, Clinician Investigator Program, McGill University Health Center and Jewish General Hospital, Montreal, QC |
| 2017-2019 | Residency, Hematology, McGill University Health Center and Jewish General Hospital, Montreal, QC |
| 2014-2017 | Residency, Internal Medicine, McGill University Health Center, Montreal, QC |
Experience & Service
Administrative Appointments/Responsibilities
Chief Fellow, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - 2023
Resident Representative, Department of Clinician Investigator Program, McGill University Health Center and Jewish General Hospital, Montreal, QC, 2019 - 2021
Co-chief Resident, Department of Hematology Residency Program, McGill University Health Center and Jewish General Hospital, Montreal, QC, 2018 - 2019
Honors & Awards
| Governor General's Academic Medal, Collège Jean-de-Brébeuf | |
| J.W. McConnell Scholarship, McGill University | |
| Dr. Clarke K. McLeod Memorial Scholarship, McGill University | |
| Summer Anatomy Prosection Bursary, McGill University | |
| Mary and Louis Streicher Prize, McGill University | |
| F. Slater Jackson Prize, McGill University | |
| Fonds de Recherche du Québec Santé (FRQS)/Ministère de la Santé et des Services Sociaux (MSSS) Training Program Bursary for Specialty Medicine Residents with an Interest in Pursuing a Research Career (Phase 1), McGill University | |
| Abstract Achievement Award, American Society of Hematology (ASH) | |
| Clinical Fellow of The Year, Leukemia Department, The University of Texas MD Anderson Cancer Center | |
| Research Fellow of The Year, Leukemia Department, The University of Texas MD Anderson Cancer Center |
Selected Publications
Peer-Reviewed Articles
- Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol None(None):None, 2024. PMID: 39671248.
- Rodriguez-Sevilla, JJ, Ganan Gomez, I, Ma, F, Chien, KS, Del Rey, M, Loghavi, S, Montalban Bravo, G, Ademà Llobet, V, Wildeman, B, Kanagal Shamanna, R, Bazinet, A, Chifotides, H, Thongon, N, Calvo, X, Hernández, JM, Díez-Campelo, M, Garcia-Manero, G, Colla, S. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun 15(1), 2024. PMID: 38499526.
- Senapati, J, Kantarjian, HM, Bazinet, A, Reville, PK, Short, NJ, Daver, N, Borthakur, G, Bataller, A, Jabbour, EJ, DiNardo, C, Haddad, FG, Sasaki, K, Popat, UR, Oran, B, Alousi, AM, Loghavi, S, Shpall, E, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. PMID: 38809547.
- Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract None(None):OP2400027, 2024. PMID: 39013130.
- Bazinet, A, Wang, A, Li, X, Jia, F, Mo, H, Wang, W, Wang, S. Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow. Cytometry B Clin Cytom 106(4):264-271, 2024. PMID: 36824056.
- Bataller, A, Gener-Ricos, G, Almanza-Huante, E, Chien, KS, Urrutia, S, Bazinet, A, Rodriguez-Sevilla, JJ, Hammond, DE, Sasaki, K, Takahashi, K, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Kadia, TM, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv 8(11):2695-2706, 2024. PMID: 38513082.
- Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica None(None):None, 2024. PMID: 38695144.
- Bazinet, A, Desikan, SP, Li, Z, Rodriguez-Sevilla, JJ, Venugopal, S, Urrutia, S, Montalban Bravo, G, Sasaki, K, Chien, KS, Hammond, DE, Kanagal Shamanna, R, Ganan Gomez, I, Kadia, TM, Borthakur, G, DiNardo, C, Daver, N, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res 30(7):1319-1326, 2024. PMID: 38300723.
- Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. Lancet Haematol 11(4):e276-e286, 2024. PMID: 38452788.
- Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. Lancet Haematol 11(4):e287-e298, 2024. PMID: 38548404.
- Bataller, A, Montalban Bravo, G, Bazinet, A, Alvarado, Y, Chien, KS, Venugopal, S, Ishizawa, J, Hammond, DE, Swaminathan, M, Sasaki, K, Issa, GC, Short, NJ, Masarova, L, Daver, N, Kadia, TM, Colla, S, Qiao, W, Huang, X, Kanagal Shamanna, R, Hendrickson, S, Ravandi-Kashani, F, Jabbour, EJ, Kantarjian, HM, Garcia-Manero, G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. Lancet Haematol 11(3):e186-e195, 2024. PMID: 38316133.
- Bataller, A, Bazinet, A, DiNardo, C, Maiti, A, Borthakur, G, Daver, N, Short, NJ, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Takahashi, K, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. PMID: 38113472.
- Thompson, PA, Bazinet, A, Wierda, WG, Tam, CS, O'Brien, S, Saha, S, Peterson, CB, Plunkett, W, Keating, M. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 142(21):1784-1788, 2023. PMID: 37595283.
- Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. PMID: 37665752.
- Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. PMID: 37334870.
- Bazinet, A, Kadia, TM, Short, NJ, Borthakur, G, Wang, SA, Wang, W, Loghavi, S, Jorgensen, JL, Patel, KP, DiNardo, C, Daver, N, Alvarado, Y, Haddad, FG, Pierce, S, Gonzalez, GN, Maiti, A, Sasaki, K, Yilmaz, M, Thompson, PA, Wierda, WG, Garcia-Manero, G, Andreeff, M, Jabbour, EJ, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv 7(13):3284-3296, 2023. PMID: 36884300.
- Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. PMID: 36458426.
- Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. PMID: 36063832.
- Bazinet, A, Heath, J, Chong, AS, Simo-Cheyou, ER, Worme, S, Polo, BR, Foulkes, WD, Caplan, S, Johnson, N, Orthwein, A, Mercier, F. Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant. Cold Spring Harb Mol Case Stud 7(3), 2021. PMID: 33986034.
- Bazinet, A, Rys, RN, Barry, A, Greenwood, CM, Young, YK, Mendoza, A, LaPorta, I, Wever, C, Mercier, F, Johnson, N. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. Leuk Lymphoma 62(10):2352-2359, 2021. PMID: 34020575.
- Estrada-Cuzcano A, Koenekoop RK, Senechal A, De Baere EB, de Ravel T, Banfi S, Kohl S, Ayuso C, Sharon D, Hoyng CB, Hamel CP, Leroy BP, Ziviello C, Lopez I, Bazinet A, Wissinger B, Sliesoraityte I, Avila-Fernandez A, Littink KW, Vingolo EM, Signorini S, Banin E, Mizrahi-Meissonnier L, Zrenner E, Kellner U, Collin RW, den Hollander AI, Cremers FP, Klevering BJ. BBS1 mutations in a wide spectrum of phenotypes ranging from nonsyndromic retinitis pigmentosa to Bardet-Biedl syndrome. Arch Ophthalmol 130(11):1425-32, 2012. PMID: 23143442.
- Majewski J, Wang Z, Lopez I, Al Humaid S, Ren H, Racine J, Bazinet A, Mitchel G, Braverman N, Koenekoop RK. A new ocular phenotype associated with an unexpected but known systemic disorder and mutation: novel use of genomic diagnostics and exome sequencing. J Med Genet 48(9):593-6, 2011. PMID: 21862673.
Other Articles
- Gener-Ricos G, Rodriguez-Sevilla JJ, Urrutia S, Bataller A, Bazinet A, Garcia-Manero G Advances in the management of higher-risk myelodysplastic syndromes: future prospects. Leuk Lymphoma 65(9):1233-1244, 2024. PMID: 38712556.
- Bazinet, A, Kantarjian, HM Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol 34(2):141-151, 2023. PMID: 36423744.
- Bazinet, A, Montalban Bravo, G New Approaches to Myelodysplastic Syndrome Treatment. Curr Treat Options Oncol 23(5):668-687, 2022. PMID: 35320468.
- Bazinet, A, Kadia, TM Changing Paradigms in the Treatment of Acute Myeloid Leukemia in Older Patients. Clin Adv Hematol Oncol 20(1):37-46, 2022. PMID: 35060961.
- Bazinet, A, Assouline, S A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’. Expert Rev Hematol 14(2):185-197, 2021. PMID: 33430671.
- Bazinet, A, Popradi, G A general practitioner’s guide to hematopoietic stem-cell transplantation. Curr Oncol 26(3):187-191, 2019. PMID: 31285665.
Letters to the Editor
- Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 147: 107602, 2024.
- Bataller, A, DiNardo, C, Bazinet, A, Daver, N, Maiti, A, Borthakur, G, Short, NJ, Sasaki, K, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
- Kim, K, Bazinet, A, Loghavi, S, Konopleva, M, Bhalla, K, Daver, N, Khoury, J, Kadia, TM, Wilson, NR, Curry, JL, Heberton, MM, Miller, D, Pierce, S, Borthakur, G, Pemmaraju, N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res 119, 2022.
Selected Presentations & Talks
National Presentations
- 2024. Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Conference. American Society of Hematology Annual Meeting 2024. San Diego, California, US.
- 2024. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia. Conference. American Society of Clinical Oncology Annual Meeting 2024. Chicago, Illinois, US.
- 2023. A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia. Conference. American Society of Hematology Annual Meeting 2023. San Diego, California, US.
- 2022. Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia. Conference. American Society of Hematology Annual Meeting 2022. New Orleans, Louisiana, US.
- 2021. A Phase I/II Study of Venetoclax in Combination with 5-Azacitidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Conference. American Society of Hematology Annual Meeting 2021. Atlanta, Georgia, US.
International Presentations
- 2024. Advances in the Treatment of Acute Myeloid Leukemia in 2024. Invited. Jewish General Hospital Medical Grand Rounds. Montreal, CA.
Formal Peers
- 2024. Advances in the Treatment of Acute Myeloid Leukemia in 2024. Montreal, QC, CA.
- 2021. Personalized Therapies in Acute Myeloid Leukemia: Bridging the Gap Between Molecular Understanding and Clinical Outcomes. Montreal, Quebec, CA.
- 2021. Single-cell Transcriptomics Applied to Acute Myeloid Leukemia in the Minimal Residual Disease State. Montreal, Quebec, CA.
- 2020. Minimal Residual Disease Measurement in CLL. Montreal, QC, CA.
- 2019. Minimal Residual Disease Measurement in CLL. Montreal, Quebec, CA.
- 2019. Blastic Plasmacytoid Dendritic Cell Neoplasm. Montreal, Quebec, CA.
- 2018. Minimal Residual Disease Measurement in CLL. Montreal, Quebec, CA.
- 2018. Minimal Residual Disease Measurement in CLL. Montreal, Quebec, CA.
Patient Reviews
CV information above last modified January 13, 2025